• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
0913693 B.C. Ltd
Acreage Holdings
AerSale Corporation - Common Stock
Alto Ingredients, Inc. - Common Stock
Amaero Inc. - Common Stock
Cartel Blue Inc
Decentral Life Inc
E2Gold Inc
FT Vest U.S. Equity Buffer & Premium Income ETF - September
Farmers & Merchants Bank of Long Beach [Ca]
Fernhill Corp
First Trust Low Duration Opportunities ETF
IES Holdings, Inc. - Common Stock
Innovation Pharmaceuticals Inc
Lipocine Inc. - Common Stock
MakeMyTrip Limited - Ordinary Shares
Maximus, Inc. Common Stock
Miata Metals Corp
Oconee Federal Financial Corp. - Common Stock
Qualys, Inc. - Common Stock
Revelation Biosciences, Inc. - Common Stock
Rockridge Resources Ltd
Satellogic Inc. - Class A Common Stock
Savaria Corp
Sezzle Inc. - Common Stock
Sigma Labs, Inc. - Common Stock
Volkswagen Ag Pfd ADR
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

6.420 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,432
Open 6.420
Bid (Size) 5.120 (100)
Ask (Size) 6.550 (100)
Prev. Close 6.420
Today's Range 6.420 - 6.420
52wk Range 2.710 - 10.31
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial ↗
October 20, 2026
Agenus (NASDAQ:AGEN) is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after... 
Via MarketBeat
News headline image
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
October 09, 2026
From Agenus Inc.
Via Business Wire

Performance

52-Week Range 37.7% below 52-week high
6.420
2.7152W Low 10.3152W High
1 Week 10.1% below 1-week high
6.001W Low 7.141W High

Agenus Inc. - Common Stock (AGEN) traded between $2.71 and $10.31 over the past 52 weeks and last traded at $6.42, 37.7% below its 52-week high. Over the past week it ranged between $6.00 and $7.14.

Past 12 Months
-1.2%
-22.9%
+15.1%
+64.2%
+98.8%
+45.2%
1W -$0.08
1M -$1.91
3M +$0.84
6M +$2.51
YTD +$3.19
1Y +$2.00

AGEN was +45.2% over the past year, +64.2% over six months, +98.8% year to date, -1.2% in the last week.

12 Months vs Market
AGEN
+45.2%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months AGEN returned +45.2% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.00× 3-mo avg
Today 1,432 3-mo avg 1.3M
1W
877.1K
1M
1.1M
3M
1.3M
6M
2.6M
YTD
1.9M
1Y
1.6M

AGEN most recently traded 1,432 shares against a 3-month average daily volume of 1.3M.

More News

Read More
News headline image
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
October 08, 2026
From Agenus Inc.
Via Business Wire
Agenus (NASDAQ:AGEN) Passes Minervini Trend Template with High Growth Momentum ↗
August 27, 2026
Via Chartmill
News headline image
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
October 03, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
October 02, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
September 10, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Participate in Upcoming September Investor Conferences
August 31, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
August 28, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
August 26, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
August 06, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
July 28, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
July 17, 2026
From Agenus Inc.
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
July 14, 2026
Via Chartmill
News headline image
Sphere 3D (NASDAQ: ANY) Engages Specialized Government Affairs Firms, Expands AI Infrastructure Strategy Across Tennessee Valley Authority Region
July 13, 2026
Via AB Newswire
Topics Artificial Intelligence
Which stocks are experiencing notable movement on Monday? ↗
July 13, 2026
Via Chartmill
Discover the most active stocks in Monday's session. ↗
July 13, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
July 13, 2026
Via Benzinga
Top stock movements in today's session. ↗
July 13, 2026
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
July 13, 2026
Via Chartmill
News headline image
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing ↗
July 13, 2026
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
July 13, 2026
Via Chartmill
News headline image
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
July 13, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
July 06, 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
June 25, 2026
From Agenus Inc.
Via Business Wire

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 6.420
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 10/20/26 04:00 PM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 2.24B
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap